JNSF PHARMA LIMITEDActive

Company number 14414547Private limited companyIncorporated 2022

Key figures

£223,699+1,006.6%
Net assets 2024/25
-100 k0100 k200 k300 k2022/232023/242024/25

Like most small UK companies, JNSF PHARMA LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2024/25
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
0250 k500 k750 k2022/232023/242024/25
Filed accounts2022/23–2024/25
2022/232023/242024/25
Total assets13,101275,808605,992
Total liabilities28,596255,594382,292
Net assets / total equity-16,09420,215223,699
Average number of employees0513

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Principal activity

Accounts 2025

The principal activity of the company during the year under review was Wholesale of pharmaceutical goods.

As described in the company's latest filed accounts.

Summary: JNSF PHARMA LIMITED

Company

JNSF PHARMA LIMITED is a private limited company registered with Companies House under company number 14414547. It was incorporated on 12 Oct 2022. Its status is active. The registered office is in Birmingham (B23). Its nature of business (SIC 2007) is wholesale of pharmaceutical goods (46460), retail sale via mail order houses or via Internet (47910), packaging activities (82920).

Accounts

The latest accounts in the database are for 2024/25 (period ending 31 Oct 2025); the company files micro-entity accounts. Net assets were £223,699, up 1,006.6% on the previous year. Total assets were £605,992 and total liabilities £382,292. The company had an average of 13 employees. Figures are available for 3 financial years (2022/23–2024/25).

Control and charges

4 persons with significant control are registered.

Filing deadlines

The next accounts are due by 31 Jul 2027. The next confirmation statement is due by 7 Apr 2027.